Was betrifft es? Warum ist das wichtig?

A Note-to-File (NF) is a useful way to document an issue or discrepancy in the conduct of a study. It also allows one to document the action taken to correct it.

 

A NF contains:

  • A factual description of the problem or issue
  • A root cause analysis
  • A description of corrective measures to prevent reoccurrence
  • A confirmation that corrective action(s) have resolved the problem, or what procedures were implemented if the issue could not be solved
  • Applicable dates and signatures

 

NFs are generated on a case-by-case basis. The content explains why things were done and the way they were done. A NF provides important information to monitors during sudy monitoring visits, during the communication with SP-INV, and potential audits and regulatory inspections (e.g. Swissmedic).

 

NF should not be misused to refrain from a protocol amendment. Repeated protocol deviations may indicate the need of an amendment.

Mehr

NF should be limited to errors that require added explanations with potential ensuing Corrective and Preventive Actions (CAPAs) to prevent re-occurrence (e.g. protocol deviations). Minor errors are usually corrected and documented elsewhere (e.g. eCRF entry corrections such as a change in recorded participant weight).

 

Who authors the NF depends on to whom the event or issue relates to, such as:

  • Site performance: the respective site delegated person writes the NF
  • Site-INV responsibilities: the Site-INV writes and signs the NF 
  • Actions taken by SP-INV or monitor: the SP-INV or delegated person writes and signs the NF

Was muss ich befolgen?

A NF is initiated and authored by the individual or organisation responsible for its content.

 

The management of NFs requires that:

  • An issue or deviation is explained, including the description of Corrective and Preventive Actions (CAPAs) to prevent reoccurrence
  • An assessment is made by the study SP-INV or Site-INV(s), regarding potential negative impact on the study`s Critical to Quality factors (e.g. participant safety, data quality, protocol compliance). Serious deviations are reported to the Ethics Committee (EC), and if appliable Swissmedic. Procedures on how to move forward with study must be defined (e.g. protocol amendment)
  • Relevant study staff is trained on the root cause of the deviation, including CAPAs to prevent deviation reoccurrence

 

NF filing:

  • Maintain an index that summarises all NFs according to topic, and where they can be located (e.g. filed in TMF and/or ISF)
  • In the event of a hard copy, write and/or print the NF on institutional paper with letterhead

Mehr

Errors or deviations can be classified according to level of seriousness. Unfortunately, there are no official guidelines that provide help on how to classify deviations. When deciding on seriousness, the study SP-INV and Site-INV(s) carry the responsibility and must use common sense, pragmatism and study experience.

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 3.10 Quality management

ICH E8(R1) – see in particular

  • 3.2 Critical to Quality Factors

ISO 31000 (access liable to costs) – see in particular section

  • Risk management: Principles and guidelines
Abkürzungen
  • CAPA – Corrective and Preventive Action
  • CTU – Clinical Trials Unit
  • eCRF – electronic Case Report Form
  • EC – Ethics Committee
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISF – Investigator Site File
  • ISO – International Organization for Standardization
  • NF – Note-to-File
  • RA – Regulatory Authorities
  • Site-INV – Site-Investigator
  • SP-INV – Sponsor-Investigator
  • TMF – Trial Master File
Conduct ↦ Quality and Risk ↦ Deviation Documentation ↦ Note to File
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Quality and Risk ↦ Deviation Documentation ↦ Note to File